A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2017
At a glance
- Drugs Trabectedin (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
- 20 Jan 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 22 Dec 2016 Planned End Date changed from 1 Sep 2018 to 1 Jun 2019.
- 25 Nov 2015 Planned End Date changed from 1 Dec 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov.